Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474240 · ClinicalTrials.gov registry record · Phase 2
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Phase 2 study, sponsored by Aegerion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
NCT00474240: Completed Phase 2 study, sponsored by Aegerion Pharmaceuticals.
NCT00474240 is a Phase 2 study that has completed, run by Aegerion Pharmaceuticals. The registered enrollment target is 157 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00474240, a Phase 2 study, has completed, sponsored by Aegerion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with moderately high cholesterol.
Interventions
- DRUG Placebo
- DRUG Atorvastatin 20 mg
- DRUG AEGR-733 5 mg
- DRUG AEGR-733 10 mg
- DRUG AEGR-733 5 mg + atorvastatin 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00474240 record still lists
NCT00474240 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00474240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00474240 about?
NCT00474240 is a clinical study titled "AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia". The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with moderately high cholesterol.
What is the current status of trial NCT00474240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2007-04. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00474240?
The interventions under investigation include: Placebo (DRUG), Atorvastatin 20 mg (DRUG), AEGR-733 5 mg (DRUG), AEGR-733 10 mg (DRUG), AEGR-733 5 mg + atorvastatin 20 mg (DRUG).
Who is sponsoring clinical trial NCT00474240?
This trial is sponsored by Aegerion Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00474240's enrollment target sits among peer trials
157 443rd of 2000 higher than 1,556 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia